#31
|
||||
|
||||
Îñòàâèì ïîêà ðàáî÷èé òåðìèí "ñêàôàíäðû".
Êîëëåãè, Antibiotic Bone Cements with FDA 510(k) Clearance ÷òî òàêîå 510(ê) Clearance? Ñïàñèáî. |
#32
|
||||
|
||||
exhaust systems - äîñëîâíî - ñèñòåìà âûïóñêà (âûäûõàåìîãî âîçäóõà)
wraparound gowns - ýòî õàëàò, êîòîðûé èìååò âîäîîòòàëêèâàþùèé äóáëèðóþùèé ñëîé, ìîæíî îáîçâàòü - èçîëèðóþùèé õàëàò. Antibiotic Bone Cements with FDA 510(k) Clearance - êîñòíûé öåìåíò ñ àíòèáèîòèêàìè, ðàçðåøåííûé ïî äîêóìåíòó 510 (ê) ÔÄÀ (èëè ñîîòâåòñòâóþùèé òðåáîâàíèÿì 510 (ê) ÔÄÀ) |
#33
|
||||
|
||||
Ñïàñèáî, à ñîáñòâåííî 510 ê ýòî ÷òî, íîìåð ïðèêàçà èëè ãîñò òàìîøíèé?
|
#34
|
||||
|
||||
Î÷åâèäíî, ýòî êàêîé-òî ñòàíäàðò, ÿ òàê äóìàþ. Îáû÷íî íîðìàòèâíûå äîêóìåíòû òàêîãî ðîäà íàçûâàþòñÿ äèðåêòèâû.
|
#35
|
||||
|
||||
ß â ãóãëå ãëÿíóë, ñëîæèëîñü âïå÷àòëåíèå ÷òî FDA áåç ýòîãî 510(k) äàæå êîôå íå ïîïüåò. Íî íå îáÿñíÿåò, ÷åãî ýòî çà êîçÿâêà òàêàÿ.
|
#36
|
||||
|
||||
Äóìàþ, ÷òî ìîæíî ïèñàòü äèðåêòèâà - íå îøèáåòåñü Ó ìåíÿ â èíñòðóêöèÿõ ê âñÿêèì êþâåçàì è ïðî÷åìó ïîñòîÿííî ëþáîé òàêîé äîêóìåíò - äèðåêòèâîé íàçûâàåòñÿ...
|
#37
|
|||
|
|||
Åñëè ÿ ïðàâèëüíî ïîíèìàþ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] î âûâîäèìîé íà àìåðèêàíñêèé ðûíîê ïðîäóêöèè, òî ýòî ñëåäóåò ïåðåâåñòè êàê "Ðàçðåøåíèå (òî÷íåå - óâåäîìëåíèå) ïî ôîðìå 510 (k)". Ñàìà ýòà ôîðìà îïèñàíà â [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]. Ó íàñ ïîäîáíûå âåùè ëþáÿò íàçûâàòü ñåðòèôèêàòàìè èëè óäîñòîâåðåíèÿìè.
|
|
#38
|
||||
|
||||
Âîïðîñ, ïî âñåé âèäèìîñòè èç îáëàñòè ñîïðîòèâëåíèÿ ìàòåðèàëîâ:
Gentamicin in concentrations of 0.5 g, 1.0 g, and 2.0 g per 40 g of Palacos acrylic bone cement has been shown to substantially reduce the shear strength of the cement, a factor that will influence crack nucleation in situations of prolonged dynamic loading. Ãåíòàìèöèí â êîíöåíòðàöèè 0,5 ã, 1,0 ã è 2,0 ã íà 40 ã öåìåíòà ìàðêè Palacos (àêðèëîâûé öåìåíò) ïðèâîäèò ê ñíèæåíèþ ïðî÷íîñòè íà ðàçðûâ, à ýòîò ïîêàçàòåëü âëèÿåò íà "íóêëåàöèþ òðåùèí" ïðè äëèòåëüíîé äèíàìè÷åñêîé íàãðóçêå. Âîïðîñ ïî ïîâîäó crack nucleation. ×òî ýòî? Ðàñïîëçàíèå òðåùèí, èëè ðàñòðåñêèâàåìîñòü èëè åùå ÷òî? Ïðîñòî "ñïîñîáñòâóåò îáðàçîâàíèþ òðåùèí"? Íàâåðíîå ïîñëåäíèé âàðèàíò ïîäîéäåò? Ìîæåò åñòü òåõíàðè íà ôîðóìå? |
#39
|
||||
|
||||
Åñòü ëè â ñîïðîìàòå òåðìèí "ÿäðà ðàñòðåñêèâàíèÿ" èëè "î÷àãè ðàçðóøåíèÿ"? Íî ýòî ÿ, ÷åñòíî, ãàäàþ, ñîïðîìàò íå ó÷èë
|
#40
|
||||
|
||||
À íà ÿçûêå îðèãèíàëà ýòî êàê áóäåò? Âîò ýòî ïðî ñîïðîìàò?
__________________
Lead, follow, or get out of the way. — Thomas Paine |
#41
|
||||
|
||||
Î÷àã ðàçðóøåíèÿ ó íèõ áûâàåò, âðîäå.
__________________
Lead, follow, or get out of the way. — Thomas Paine |
#42
|
||||
|
||||
crack nucleation
òåõ. çàðîæäåíèå òðåùèí; çàðîæäåíèå òðåùèíû ýëåêòð. îáðàçîâàíèå òðåùèí |
#43
|
||||
|
||||
Êîëëåãè, ïîäñêàæèòå ïîæàëóéñòà, êàê áû ïåðåâåñòè íà ðóññêèé
Center for Disease Control and Prevention. Èíòåðåñóåò, òàê ñêàçàòü, îôèöèàëüíûé ïåðåâîä. Åñëè â ðóññêîé ëèòåðàòóðå óæå çàïóùåí êàêîé-ëèáî óñòîÿâøèéñÿ âàðèàíò, áóäó áëàãîäàðåí, ÷òîá íå ïëîäèòü íîâûå. Ìîé ñàäæåñò: Ãîñóäàðñòâåííûé Öåíòð Ïðîôèëàêòèêè è Ëå÷åíèÿ çàáîëåâàíèé ÑØÀ. Ñïàñèáî. |
#44
|
||||
|
||||
Öèòàòà:
|
#45
|
||||
|
||||
Ñïàñèáî.
|